Update – UPDATE

RIBOXX PHARMACEUTICALS and ONC BIO announce

an exclusive license agreement for immunotherapy of certain cancers  

with the Best-in-Class TLR3-ligand RIBOXXIM®

November 18, 2019 — Radebeul (Germany) & Seattle (USA) — RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor 3 (TLR3) and RIG-I-like-Receptor (RLR) ligands, and ONC Bio, a biotech company developing new therapeutic strategies in cancer, today announced that they have signed a license agreement that grants ONC Bio exclusive global development and commercialization rights to a new drug development program to treat certain cancers.

ONC Bio will start Phase I clinical studies in 2020 and under the terms of the license agreement, will assume sole responsibility for global development and commercialization of RIBOXXIM drug product for treatment of certain cancers. Riboxx will be responsible for manufacturing and supply of RIBOXXIM to ONC Bio.  

RIBOXXIM is a best-in-class Toll-like Receptor 3 (TLR3)-ligand manufactured with the patented process TENPORA® of RIBOXX in full compliance with the GMP requirements of the EU competent regulatory authority, and with the GMP specifications of the experimental drug. 

RIBOXXIM is a proprietary drug product of RIBOXX PHARMACEUTICALS. It activates the innate immune system to eliminate cancer cells as a validated approach in immuno-oncology as performed with the historical TLR3 ligand poly(I:C) and its derivates. 

RIBOXXIM has been validated in multiple pre-clinical studies in immunotherapy of cancer. It displays unique physical, chemical and biological properties, as well as optimal bioavailability with increased stability to degradation in body fluids such as human plasma. RIBOXXIM is stable in liquid form as a drug product for several years. 

Jacques Rohayem, CEO & CSO of RIBOXX PHARMACEUTICALS declared: “We are very thrilled to start this collaboration with ONC Bio, a US-based company with a very strong scientific expertise in cancer immunotherapy. This collaboration gives Riboxx access to the market in the USA and North America and expands the portfolio of Riboxx drug development programs such as APOXXIM, RIBOXXON, and RIBOXXOL, mainly focusing on cancer immunotherapy.” 

Steven Reed, CEO of ONC BIO stated: “ONC Bio is very pleased to start this collaboration towards the development of a new and unique therapeutic strategy in cancer. The potential of TLR3-Ligands such as RIBOXXIM to treat cancer has been extensively studied in the past decades by scientists at ONC Bio and has the potential to contribute significantly to ONC Bio’s immunotherapy approaches.” 

About RIBOXX PHARMACEUTICALS

RIBOXX PHARMACEUTICALS is a biotech company developing proprietary Toll-like-receptor (TLR) ligands and RIG-I-like-Receptor (RLR) ligands for applications in cancer immunotherapy. RIBOXX IP portfolio includes 17 PCT patent families so far, with 8 PCT patents granted in USA, EU and/or Japan. 

About ONC BIO 

ONC Bio Corp. is a biopharmaceutical company developing drugs for immunotherapy of cancer. ONC Bio products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies.  

For further information, please contact

Prof. Dr. Jacques ROHAYEM, CEO & CSO

RIBOXX PHARMACEUTICALS 

www.riboxx-pharma.com

Steven G. Reed, CEO

ONC Bio Corp.